Neumega (Genetics Institute Inc)
Neumega (Genetics Institute Inc) Brand names, Neumega (Genetics Institute Inc) Analogs
Neumega (Genetics Institute Inc) Brand Names Mixture
- No information avaliable
Neumega (Genetics Institute Inc) Chemical_Formula
C854H1411N253O235S2
Neumega (Genetics Institute Inc) RX_link
http://www.rxlist.com/cgi/generic3/oprelvek.htm
Neumega (Genetics Institute Inc) fda sheet
Neumega (Genetics Institute Inc) msds (material safety sheet)
Neumega (Genetics Institute Inc) Synthesis Reference
No information avaliable
Neumega (Genetics Institute Inc) Molecular Weight
19047.2
Neumega (Genetics Institute Inc) Melting Point
No information avaliable
Neumega (Genetics Institute Inc) H2O Solubility
No information avaliable
Neumega (Genetics Institute Inc) State
Liquid
Neumega (Genetics Institute Inc) LogP
-0.070
Neumega (Genetics Institute Inc) Dosage Forms
Powder for solution; Solution (subcutaneous injection)
Neumega (Genetics Institute Inc) Indication
Increases reduced platelet levels due to chemotherapy
Neumega (Genetics Institute Inc) Pharmacology
Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Oprelvekin is stimulation of megakaryocytopoiesis and thrombopoiesis. Oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis
Neumega (Genetics Institute Inc) Absorption
No information avaliable
Neumega (Genetics Institute Inc) side effects and Toxicity
No information avaliable
Neumega (Genetics Institute Inc) Patient Information
No information avaliable
Neumega (Genetics Institute Inc) Organisms Affected
Humans and other mammals
